Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
Laure Hirsch(Harvard University), Toni K. Choueiri(Harvard University), Ronan Flippot(Institut Gustave Roussy), Priscilla K. Brastianos(Massachusetts General Hospital), Bashar Abuqayas(University of Iowa), Nityam Rathi(Cleveland Clinic), Philippe Barthélémy(Centre National de la Recherche Scientifique), Hannah Dzimitrowicz(Duke Medical Center), Amir Mortazavi(The Ohio State University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Andreas Varkaris(Massachusetts General Hospital), Emmanuel Seront, Subrina Farah(Dana-Farber Cancer Institute), Mehmet Asım Bilen(Emory Healthcare), Yousef Zakharia(University of Iowa), Katharine A. Collier(The Ohio State University), Jonathan Thouvenin(Hospices Civils de Lyon), Lauren C. Harshman(Dana-Farber Cancer Institute), Rana R. McKay(University of California San Diego), I. Alex Bowman(The University of Texas Southwestern Medical Center), Wenxin Xu(Dana-Farber Cancer Institute), Wanling Xie(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Nieves Martínez Chanzá(Institut Jules Bordet), Laurence Albigès(Université Paris-Saclay), Elaine T. Lam(University of Colorado Cancer Center), Neeraj Agarwal(University of Utah), Katherine M. Krajewski(Brigham and Women's Hospital), Guillermo de Velasco(Dana-Farber Cancer Institute), Michael R. Harrison(Pfizer (United States))
Cited by 95
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k